Skip to main content
. Author manuscript; available in PMC: 2010 Dec 20.
Published in final edited form as: Cancer. 2010 Jun 1;116(11):2655–2664. doi: 10.1002/cncr.25055

Figure 5. Angiogenesis and lymphangiogenesis characterization in MCL.

Figure 5

A. VEGFR-1 is expressed by MCL B-cells (A1) and neovessels (v = vessel) (A2) by immunofluorescence analysis, and appears to be overexpressed in neoplastic B-cells (n=5) compared to normal B-cells (n=5) and MCL cell line Jeko-1 by quantitative PCR analysis (A3). B. VEGFR-2 expression in neovasculature. B1: VEGFR-2 immunohistochemistry on frozen tissue section. B2: A majority of VEGFR-2+ tumor endothelial cells coexpress CD34 by immunofluorescence analysis (white arrows). B3: VEGFR-2 vessels (V) are situated in proximity to VEGF-producing tumor cells (B3). C. Lymphangiogenesis as marked by VEGFR-3+ (C1), podoplanin+ (C2) and Lyve-1+ (C3). Some lymphatic vessels appear to co-express CD34. Black arrows point to CD34+podoplanin+ vessels, and asterisks point to CD34+lyve-1+ vessels.

HHS Vulnerability Disclosure